Skip to main content
ERYTECH Pharma S.A. logo

ERYTECH Pharma S.A. — Investor Relations & Filings

Ticker · ERYP ISIN · FR001400K4B1 LEI · 969500U8ZZCODU8A9374 PA Manufacturing
Open in API
Filings indexed 864 across all filing types
Latest filing 2025-06-18 Delisting Announcement
Country FR France
Listing PA ERYP

About ERYTECH Pharma S.A.

https://phaxiam.com/

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Delisting Announcement Classification · 1% confidence The document is a short announcement dated June 18, 2025, stating that PHAXIAM Therapeutics has requested the suspension of its stock listing on Euronext Paris until the delisting procedure is completed. The key phrases are 'suspension de la cotation' (suspension of listing) and 'radiation des titres' (delisting of securities). This directly relates to the status of the company's stock trading on an exchange. Among the provided codes, 'DLST' (Delisting Announcement) is the most appropriate category for an official notice regarding the removal or suspension leading to removal from a stock exchange. The document length is short (2093 chars) and functions as a direct announcement, not a comprehensive report.
2025-06-18 French
Inside Information / Other news releases
Delisting Announcement Classification · 1% confidence The document is a formal announcement from PHAXIAM Therapeutics dated June 18, 2025. The headline explicitly states: 'PHAXIAM Therapeutics announces the suspension of trading in its shares until delisting.' The text confirms that the company requested Euronext to suspend trading pending the completion of the delisting procedure. This directly corresponds to the definition of a Delisting Announcement (DLST). The document length is short (2011 chars), but its content is a direct, primary announcement of the delisting action, not just an announcement of a report.
2025-06-18 English
Informations privilégiées / Autres communiqués
Delisting Announcement Classification · 1% confidence The document explicitly announces that PHAXIAM Therapeutics is undergoing 'liquidation judiciaire' (judicial liquidation) following a decision by the Commercial Court of Lyon. It further states that the company 'sollicitera auprès d'Euronext la radiation de ses actions' (will request the delisting of its shares from Euronext). The core subject is the cessation of operations and the removal from the stock exchange. This directly corresponds to the definition of a Delisting Announcement (DLST). Although liquidation is a severe event, the primary action being communicated to the market, especially concerning the stock, is the impending delisting.
2025-06-12 French
Inside Information / Other news releases
Delisting Announcement Classification · 1% confidence The document explicitly announces the 'judicial liquidation' of PHAXIAM Therapeutics and states that the company 'will request the delisting of its shares from Euronext.' The core subject matter is the cessation of operations and the subsequent removal of the stock from the exchange. This directly aligns with the definition of a Delisting Announcement (DLST). Although liquidation is mentioned, the primary action being communicated to the market regarding its listing status is the delisting request.
2025-06-12 English
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 1% confidence The document is a short announcement (2376 characters) in French regarding a court decision to postpone a hearing concerning takeover offers ('audience d'examen des offres') for PHAXIAM Therapeutics, and mentions the subsequent likely conversion to judicial liquidation and delisting request. This is not a full financial report (like 10-K or IR), nor is it a standard earnings release (ER) or dividend notice (DIV). It specifically concerns legal/court proceedings impacting the company's structure and future, including the mention of a 'redressement judiciaire' (receivership) and potential liquidation. This fits best under 'Legal Proceedings Report' (LTR) as it details an update on a significant legal/insolvency matter. It could also be considered a general regulatory filing (RNS), but LTR is more specific to the content about court hearings and insolvency status.
2025-06-05 French
Inside Information / Other news releases
Delisting Announcement Classification · 1% confidence The document announces a postponement of a court hearing related to an offer review by PHAXIAM Therapeutics. Crucially, it states that following the hearing, the court will pronounce the conversion of judicial reorganization into judicial liquidation, and consequently, the Company will request the 'delisting of PHAXIAM shares from Euronext.' The core subject matter is the impending delisting action resulting from legal/financial distress proceedings. This directly aligns with the definition for Delisting Announcement (DLST). Although it mentions legal proceedings (LTR), the primary actionable announcement is the delisting itself.
2025-06-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.